MESSAGE FROM THE ASSEMBLY CHAIR

As I finish my two-year term, I am pleased that we have been able to make substantial progress on the objectives that were outlined last year. Specifically, we have seen the initiation of MTPI-sponsored on-line Journal Clubs and Webinars, have seen the design and implementation of a much improved webpage, have seen the initiation and implementation of not one but three MTPI-sponsored awards, have seen increasing opportunities for our fellows and younger faculty members in MTPI, and have begun to work to find increasing opportunities for our international members. To enable these activities, we have formed the MTPI Awards & Recognition Working Group (Henry Koziel, Chair), an International Working Group (Antoni Torres, Chair), and continue to benefit from efforts and talent of the Membership Working Group (Charles Dela Cruz and Robert Blount, Co-Chairs). These are terrific achievements, and due in large part to the dedicated efforts of an energetic and capable executive committee, and enabled by the staff of the ATS. In particular, I would like to thank Miriam Rodriguez, Sean Slifer, and Bridget Nance for their work on the MTPI assembly.

The Assembly, Microbiology, Tuberculosis, and Pulmonary Infections (MTPI) is a “big tent”, bringing together those with backgrounds in laboratory medicine, public health, the host response to infections, as well as clinicians. This has allowed the Assembly to craft “signature” ATS Statements such as those on Hospital and Ventilator Associated Pneumonia, Community Acquired Pneumonia, and on the Diagnosis and Treatment of TB, and well as to sponsor a compelling array of sessions of both scientific and clinical interest.

Joe Keane chairs the Planning Committee. Joe continues the MTPI legacy of crafting high impact statements, and during his tenure we have seen ongoing work on the Hospital and Ventilator Associated Pneumonia, Treatment of Latent TB Infection, Targeted Testing for Latent TB Infection, Community Acquired Pneumonia, and TB Treatment. Each of these statements represents...

(Continued on page 2)
a collaborative effort across different professional societies, and will be done using the GRADE guidelines. Additionally, we have sponsored two new initiatives: Defining a Research Agenda for Non-Tuberculosis Mycobacterial Infections, (Charles Daley, ATS Chair) and Clinical Practice Guidelines for Non-tuberculous Mycobacterial Infection (Joint ATS/ ERS Application) (Charles Daley, ATS Chair).

Grant Waterer (Chair) and Kevin Fennelly (Chair-Elect) are the Program Chairs. This is without doubt the most difficult job in the Assembly, and I am particularly proud of the program they have crafted this year for ATS 2014. In addition to managing the broad array of abstracts our assembly receives, they have been particularly successful in partnering with seven other ATS assemblies. As a result, our program this year should appeal to broad range of interests. Additionally, this years’ programming continues our efforts to involve and feature our members who are early in their careers in Pulmonary medicine.

Henry Koziel chairs the Nominating Committee, tasked with selecting candidates for the MTPI leadership. He is working with Tim Sterling and Carlos Luna. As a member of the Executive Committee, Henry’s insight is invaluable.

Scott Evans has served as our Web and Communications Director. Scott has already approached this position with a great deal of energy, and I will describe below his efforts playing a central role in the direction of our Assembly for the next two years.

Charles Dela Cruz and Robert Blount are co-chairs of the Junior Membership Working Group. This committee was formed by Laurence Huang, and has been tasked with enhancing opportunities for participation in MTPI, and with developing strategies for improved mentorship.

Antoni Torres serves on the committee as our International Representative. Antoni assembled and chaired the International Working Group.

Phil LoBuie serves on the committee as the CDC representative. MTPI has had a long-standing interest in public health, such that the CDC has representatives on our Planning and Program Committees.

I would like to acknowledge how privileged I have been to work with the MTPI membership and with the ATS. Most of us know that our work with the assembly is not our “Day Job”, and yet the energy, dedication, and creativity that is manifest in our small assembly is wonderful and energizing. The ATS is unusual in that it is a “bottom up” organization, with each assembly playing an essential role in all aspects of the society. Here, the dedication of the ATS staff and leadership is unparalleled, and I would encourage you that are new to the ATS to find ways to become more involved.

Finally, more personally, I would ask that you consider contributing to the ATS Foundation. For me, small awards from the ALA and NIH early in my career made all the difference.
Our MPTI membership includes many opinion leaders in pulmonary infection, diagnostics and treatment. An important role of the Planning Committee is to generate reference documents such as guidelines and position papers that exploit this resource of pulmonary infection scholars. As expected then, the MTPI Planning Committee has had a busy, productive and challenging year. At our annual face-to-face meeting at the ATS International Conference in Philadelphia 2013, the committee reviewed the status of active projects and discussed new submissions. In a subsequent teleconference, the committee reviewed, scored and prioritized applications for ATS funding consideration.

Summary of progress to date:

(1) Update on Active MTPI Assembly projects: The following active projects represent proposals that were favorably reviewed by the ATS Program Review sub-committee, recommended for approval to the ATS Finance Committee, and approved for funding by the ATS Board of Directors. We were fortunate to receive continued support for the following projects:

- Updated guidelines for the diagnosis and treatment of HAP and VAP, (Mark Metersky, ATS Co-Chair, Andre Kalil, IDSA Co-Chair).
- Targeted tuberculosis testing and treatment of latent TB infection update (Carol Hamilton, ATS Co-Chair, Tim Sterling IDSA Co-Chair; John Jereb CDC Co-Chair).
- ATS/IDSA Community Acquired Pneumonia Guidelines (Grant Waterer, ATS Co-Chair). Whereas last year this project failed to receive funding from the ATS (for non-assembly reasons), this year, thankfully, the process got underway and we look forward to a successful outcome.
- Revision of the ATS CDC IDSA 2003 TB treatment statement (Payam Nahid, ATS Chair).
- Diagnostic Standards and Classification of Tuberculosis in Adults and Children (David Lewinsohn, Chair).

(2) New MTPI Assembly Project Proposals: In a year that was difficult for proposers, and characterized by an ATS requirement to fulfill the PICO question format (P=Patient problem or population, I=intervention, C=comparison and O=outcomes), we were reassured that two proposals went forward for budgeting.

- Defining a Research Agenda for Non-Tuberculosis Mycobacterial Infections, (Charles Daley, ATS Chair)
- Clinical Practice Guidelines for Non-tuberculous Mycobacterial Infection (Joint ATS/ ERS Application) (Charles Daley, ATS Chair).

The MTPI Planning Committee continues to function as a liaison between the MTPI Membership and the MTPI Assembly Chair. We welcome your ideas, comments, criticisms and suggestions. We also encourage individuals to identify themselves if they would like to participate more actively in future MTPI Planning Committees. The next ATS meeting is nearly upon us, so please begin to think of additional assembly projects for next year.

As I complete my first year as the Planning Committee Chair, I would like to thank David Lewinsohn (the current MTPI Assembly Chair) and Henry Koziel (the immediate past Planning Committee Chair) for their advice and support.
Thank you for the tireless efforts and generous contributions of time of the MTPI Committee Members over the last year: Charles Daley, Carol Hamilton, Max Salfinger, Kristina Crothers, Grant Waterer, Stephen Gordon, Mark Metersky, Payam Nahid, Charles Dela Cruz, Chadi Hage, Adithya Cattamanchi, and Scott Evans. The next MTPI Planning Committee meeting will be at the ATS 2014 International Conference in San Diego, CA.


** Specifically: MTPI will discuss the ATS requirements for new proposals at the business meeting in San Diego. Please email jkeane@stjames.ie or a member of the committee if you are interested in planning or submitting an MTPI project proposal, or if you have any questions about the new ATS proposal process for a successful application.

---

**PROGRAM COMMITTEE REPORT**

Grant Waterer, MBBS, PhD, Chair, and Kevin Fennelly, MD, MPH, Chair-Elect

Our main agenda is to answer the meeting requirement for a comprehensive syllabus, while remaining true to that unique ATS gift - which is to bring to you, the fresh and exciting research questions that drive thinking and innovation in our field of pulmonary infections.

As usual, two face-to-face International Conference Committee (ICC) planning committee meetings took place in September and December, where Grant Waterer, Chair of the Program Committee, and Kevin Fennelly, Chair-Elect, represented MTPI. They programmed around 400 submitted abstracts into presentations that we hope will promote the academic and clinical activity our members, while stimulating interest in pulmonary infection – which will attract new people to our assembly.

This year we have programmed four Mini Symposia. **Featured speakers include Robert Wilkinson (TB), Rebecca Prevots and Ken Olivier (NTM), Michelle Prickett and James Chalmers (Non-CF bronchiectasis) and Jerry Brown (lung immunity).** We will have four Poster Discussion, and ten Thematic Poster sessions. Thematic Poster sessions will have teams of at least 2 or more facilitators viewing each poster to allow increased interaction between facilitators and presenters. For most sessions, experienced facilitators have been paired with more junior facilitators to provide junior members the opportunity for greater involvement and to learn from more senior mentors. The abstract sessions present exciting results of cutting-edge research on mycobacterial and...
non-mycobacterial topics, including results of clinical trials, epidemiologic studies, and novel insights into mechanisms of host defense. Two Thematic Poster sessions are dedicated to case reports of unusual manifestations of pulmonary infections.

In addition to the scientific abstract sessions, MTPI has programmed four major Scientific Symposia with highly respected international speakers, and we are co-sponsoring seven other sessions with other assemblies. In addition, we are sponsoring Meet-the-Professor Seminars, and Sunrise Seminars.

Overall, we have a full docket of MTPI sessions over the 4-day conference that will interest our members, and provide insight into scientific advances and updates on clinical care.

Finally, we would like to acknowledge and thank each of the committee members for their service, hard work and input into the programming during the past year.


ATS members are clinically and academically inquisitive, and we have developed a program that should address that curiosity. See you all in San Diego May 2014!

### ATS 2014 - San Diego
#### Sessions Sponsored by the Assembly on Microbiology, Tuberculosis and Pulmonary Infections

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Session Title</th>
<th>Session Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Postgraduate Courses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Friday, May 16, 2014</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PG6</td>
<td>DIFFICULT CLINICAL PROBLEMS IN PULMONARY INFECTIONS</td>
<td>8:00 AM - 4:00 PM</td>
</tr>
<tr>
<td><strong>Saturday, May 17, 2014</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PG17</td>
<td>HOST DEFENSE MECHANISMS IN PULMONARY INFECTION</td>
<td>8:00 AM - 4:00 PM</td>
</tr>
<tr>
<td><strong>Scientific Symposium</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sunday, May 18, 2014</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A87</td>
<td>THERE IS NOTHING LATENT ABOUT LATENT TB</td>
<td>2:00 PM - 4:30 PM</td>
</tr>
<tr>
<td><strong>Monday, May 19, 2014</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B7</td>
<td>MACROLIDES IN RESPIRATORY INFECTIONS: PANACEA OR PANDORA'S BOX?</td>
<td>8:15 AM - 10:45 AM</td>
</tr>
<tr>
<td><strong>Tuesday, May 20, 2014</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C5</td>
<td>IDENTIFYING AND TREATING PATIENTS WITH MULTI-DRUG RESISTANT COMMUNITY-ACQUIRED PNEUMONIA</td>
<td>8:15 AM - 10:45 AM</td>
</tr>
<tr>
<td>C90</td>
<td>MULTI-DRUG RESISTANT AND EXTENSIVELY-DRUG RESISTANT TB: CRITICAL ELEMENTS FOR PROGRESS</td>
<td>2:00 PM - 4:30 PM</td>
</tr>
<tr>
<td>Session Code</td>
<td>Session Title</td>
<td>Session Time</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td><strong>Jointly-Developed Symposium</strong></td>
<td><strong>Sunday, May 18, 2014</strong></td>
<td></td>
</tr>
<tr>
<td>A11</td>
<td>INFLUENZA VIRUS PNEUMONIA: VIRUS-HOST INTERACTIONS, DETERMINANTS OF LUNG PATHOGENICITY, AND CLINICAL ASPECTS</td>
<td>8:15 AM - 10:45 AM</td>
</tr>
<tr>
<td><strong>Sunrise Seminars</strong></td>
<td><strong>Tuesday, May 20, 2014</strong></td>
<td></td>
</tr>
<tr>
<td>SS212</td>
<td>HIV INFECTION IN ASTHMA AND COPD: CAUSE AND EFFECT</td>
<td>7:00 AM - 8:00 AM</td>
</tr>
<tr>
<td>SS219</td>
<td>INTERPRETING QUANTIFERON TB DATA</td>
<td>7:00 AM - 8:00 AM</td>
</tr>
<tr>
<td><strong>Wednesday, May 21, 2014</strong></td>
<td><strong>SS313</strong> UNDERSTANDING TUBERCULOSIS THROUGH THE LENS OF GENOMICS</td>
<td>7:00 AM - 8:00 AM</td>
</tr>
<tr>
<td><strong>Meet The Professor Seminars</strong></td>
<td><strong>Sunday, May 18, 2014</strong></td>
<td></td>
</tr>
<tr>
<td>MP409</td>
<td>TUBERCULOSIS AND THE TNF-ALPHA INHIBITORS</td>
<td>12:00 PM - 1:00 PM</td>
</tr>
<tr>
<td><strong>Monday, May 19, 2014</strong></td>
<td><strong>MP508</strong> CHALLENGING CASES IN FUNGAL LUNG INFECTIONS: DIAGNOSTIC AND THERAPEUTIC INSIGHTS</td>
<td>12:00 PM - 1:00 PM</td>
</tr>
<tr>
<td><strong>Mini-Symposium</strong></td>
<td><strong>Sunday, May 18, 2014</strong></td>
<td></td>
</tr>
<tr>
<td>A15</td>
<td>TUBERCULOSIS GENOMICS</td>
<td>8:15 AM - 10:45 AM</td>
</tr>
<tr>
<td><strong>Thursday, May 20, 2014</strong></td>
<td><strong>C16</strong> IMMUNITY PATHWAYS IN THE LUNG</td>
<td>8:15 AM - 10:45 AM</td>
</tr>
<tr>
<td>C97</td>
<td>NON-CYSTIC FIBROSIS BRONCHIECTAS</td>
<td>2:00 PM - 4:30 PM</td>
</tr>
<tr>
<td><strong>Wednesday, May 21, 2014</strong></td>
<td><strong>D108</strong> PNEUMONIA EPIDEMIOLOGY AND OUTCOMES</td>
<td>2:00 PM - 4:30 PM</td>
</tr>
<tr>
<td><strong>Poster Discussion Sessions</strong></td>
<td><strong>Sunday, May 18, 2014</strong></td>
<td></td>
</tr>
<tr>
<td>A27</td>
<td>HIV AND THE LUNG</td>
<td>8:15 AM - 10:45 AM</td>
</tr>
<tr>
<td><strong>Monday, May 19, 2014</strong></td>
<td><strong>B24</strong> DIAGNOSIS AND TREATMENT IN THE SPECTRUM OF TUBERCULOSIS</td>
<td>8:15 AM - 10:45 AM</td>
</tr>
<tr>
<td><strong>Tuesday, May 20, 2014</strong></td>
<td><strong>C27</strong> DIAGNOSIS AND TREATMENT OF NONTUBERCULOS MYCOBACTERIA INFECTIONS</td>
<td>8:15 AM - 10:45 AM</td>
</tr>
<tr>
<td>C105</td>
<td>ENVISIONING AND TESTING NEW THERAPEUTIC APPROACHES TO PNEUMONIA</td>
<td>2:00 PM - 4:30 PM</td>
</tr>
<tr>
<td><strong>Wednesday, May 21, 2014</strong></td>
<td><strong>D108</strong> PNEUMONIA EPIDEMIOLOGY AND OUTCOMES</td>
<td>2:00 PM - 4:30 PM</td>
</tr>
<tr>
<td>D109</td>
<td>EPIDEMIOLOGY OF NONTUBERCULOUS MYCOBACTERIA INFECTIONS: DISTRIBUTION AND RISK FACTORS</td>
<td>2:00 PM - 4:30 PM</td>
</tr>
<tr>
<td>Session Code</td>
<td>Session Title</td>
<td>Session Time</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>A50</td>
<td>INFECTIONS IN THE IMMUNOCOMPROMISED</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>A51</td>
<td>NEW INSIGHTS INTO PATHOGENS AND HOST DEFENSE</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>A52</td>
<td>INFECTIOUS DISEASES CASE REPORTS I</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>A53</td>
<td>INFECTIOUS DISEASES CASE REPORTS II</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>B51</td>
<td>TUBERCULOSIS: DIAGNOSIS</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>B52</td>
<td>TUBERCULOSIS: TREATMENT</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>B53</td>
<td>TUBERCULOSIS: EPIDEMIOLOGY</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>C48</td>
<td>COMMUNITY AND HEALTH CARE ASSOCIATED PNEUMONIA</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>D50</td>
<td>HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED PNEUMONIA</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
<tr>
<td>D51</td>
<td>NON-CYSTIC FIBROSIS BRONCHIECTASIS</td>
<td>8:15 AM - 4:30 PM</td>
</tr>
</tbody>
</table>
Please note the following FEATURED INVITED SPEAKERS at this year’s MTPI Symposium and Mini-Symposiums:

**Dr. Robert Wilkinson**
Dr. Wilkinson is a Wellcome Trust Senior Fellow and Professor of Infectious Diseases at the University of Cape Town and is an internationally recognized expert in translational science of TB. Dr. Wilkinson will be giving two talks the following times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, May 18, 2014</td>
<td>2:00 PM</td>
<td>THERE IS NOTHING LATENT ABOUT LATENT TB</td>
</tr>
<tr>
<td>A8</td>
<td>4:30 PM</td>
<td>TUBERCULOSIS GENOMICS</td>
</tr>
<tr>
<td>A1</td>
<td>8:15 AM</td>
<td>IMMUNITY PATHWAYS IN THE LUNG</td>
</tr>
<tr>
<td>A1</td>
<td>10:45 AM</td>
<td>NON-CYSTIC FIBROSIS BRONCHIECTASIS</td>
</tr>
<tr>
<td>C16</td>
<td>2:00 PM</td>
<td>IMMUNITY PATHWAYS IN THE LUNG</td>
</tr>
<tr>
<td>C16</td>
<td>4:30 PM</td>
<td>NON-CYSTIC FIBROSIS BRONCHIECTASIS</td>
</tr>
</tbody>
</table>

**Dr. Jerry Brown**
Dr. Brown is a Professor of Respiratory Infection at the University College of London. He is an internationally recognized expert in the molecular and host immune pathogenesis of lung infection.

**Dr. Michelle Prickett**
Dr. Prickett is an Assistant Professor at Northwestern University Feinberg School of Medicine. Her expertise lies in the area of chronic infections and CF and non-CF bronchiectasis.

**Dr. James Chalmers**
Dr. Chalmers is a Wellcome Trust Fellow and Clinical Lecturer in the Division of Molecular Microbiology in the College of Life Sciences, University of Dundee. He is an expert in the area of respiratory infections, pneumonia and bronchiectasis.

**Dr. Becky Prevots & Dr. Ken Olivier**
Drs. Becky Prevots and Ken Olivier are both from the Laboratory of Clinical Infectious Diseases in the NIAID, NIH.
- Dr. Prevots is a major leader in studies of the epidemiology of non-tuberculous mycobacterial (NTM) infections in the U.S.
- Dr. Olivier is an internationally recognized expert in the clinical epidemiology, pathogenesis, and treatment of NTM infections.
Congratulations to the following award recipients

These 20 abstract presenters will receive their Abstract Scholarships at our MTPI Membership Meeting, Monday, May 19th, 5-7pm, Manchester Grand Hyatt San Diego, Harbor Ballroom B-C, Second Floor

1. **Ranu Surolia**, University of Alabama at Birmingham, Attenuation Of HO-1 Responses In The Elderly Predisposes To NTM Infections
2. **Mark Bernard**, Beth Israel Deaconess Medical Center, HIV-encoded miRNAs engage macrophage Toll-like receptor 8 and promote TNF release.
3. **Yasir Tarabichi**, UCLA, Administration Of Intranasal Live Attenuated Influenza Induces Changes In Both The Nasal Microbiome And Microarray Expression Profiles
4. **Robert Dickson**, University of Michigan, A Comparison Of Three Methods Of Identification Of Bacteria In Bronchoalveolar Lavage Specimens
5. **Ali Rashidian**, UCSF Fresno, Utility Of Laboratory Studies In Diagnosing Lung Nodules Due To Coccidioidomycosis
6. **Paula Griffith**, Univ Utah, Triage And Outcomes Of Emergency Department Patients With Parapneumonic Effusion
7. **Chad Marion**, Yale University, Chitinase 3-like 1 (Chi3l1) Augments Bacterial Clearance While Suppressing Neutrophilic Pulmonary Inflammation In Pseudomonas Pneumonia
8. **Kohei Fujita**, Kyoto University, Prevalence And Risk Factors For Chronic Co-Infection In Pulmonary Mycobacterium Avium Complex Disease
9. **Brittan Scales**, University of Michigan, Persistent Inflammation Leads To Community-Wide Changes In The Murine Lung Microbiome, Including A Bloom Of Pseudomonas Fluorescens
10. **Fadie Coleman**, Microbiology Department; Pulmonary Center, BUSM, Alveolar Macrophage NF-kB-driven Lung Defense Is Circumvented By Virulent Pneumococci
11. **Barbara Jones**, University of Utah, Going Big: Five Year Trends In Antibiotic Use For Hospitalized Pneumonia Patients in National VA Data, 2006-2010
12. **Mehdi Mirsaeidi**, University of Illinois at Chicago, Nontuberculous Mycobacterial Disease Mortality In The United States, 1999-2010: A Population-Based Comparative Study
13. **Joshua Danley**, Lankenau Medical Center, Women With Pulmonary Nontuberculous Mycobacterial Infection Have Normal Estrogen Levels, But Lower DHEA Levels Compared With Age-Matched Controls
14. **Jason Arnason**, The University of Calgary, Co-Infection With Human Rhinovirus And Bacteria Modulates The Innate Host Response Through The Dysregulation Of Antimicrobial Peptide Expression
15. **Samantha Yeligar**, Emory University / Atlanta VA Medical Center, HIV Infection Induces Dysregulation Of PPAR-? And TGF In Alveolar Macrophages Of Otherwise Healthy Subjects
16. **Byeong-Ho Jeong**, Samsung Medical Center, Sungkyunkwan University School of Medicine, Oral Macrolide Therapy After An Initial 2 Weeks Of Combination Antibiotics For Treating Mycobacterium massiliense Lung Disease
17. **Raj Shah**, Northwestern University Feinberg School of Medicine, The Diagnostic Utility Of Bronchoalveolar Neutrophils And Serum Procalcitonin For Pneumonia In Intubated Patients
18. **Vikas Anathy**, University of Vermont, Glutaredoxin-1 Attenuates S-Glutathionylation Of The Death Receptor Fas And Decreases Resolution Of Pseudomonas Aeruginosa Pneumonia
19. **M Leigh Anne Daniels**, University of North Carolina, Dural Ectasia On Lumbosacral MRI And Chest CT In Idiopathic Bronchiectasis Patients: Phenotypic Overlap With Hereditable Connective Tissue Disorders
20. **Sebastian Kurz, MD, PhD** University Hospitals Cleveland Case Medical Center, Structural And Functional Characterization Of The Highly Effective Boronate-Transitional-State-Inhibitor (BATSI), EC19, Of The Mycobacterium Tuberculosis Beta-Lactamase BlaC
We would also like to acknowledge the following abstracts by fellows and junior investigators
(from both the US and International abstract submissions)

**Fellows**

1. **Keira Cohen**, Brigham & Women's Hospital, Whole Genome Sequencing M. tuberculosis Strains In Kwa-Zulu-Natal Reveals Multiple Lineages And Extensive Diversity Of MDR And XDR-TB
2. **Andrew Graustein**, University of Washington, A Polymorphism In The TLR9 Gene Region Is Associated With Susceptibility To Tuberculosis In Vietnam
3. **Allen Griffin**, University of Louisville, Modulation Of The Renin-Angiotensin-Aldosterone Pathway In Community-Acquired Pneumonia: Results From The Community-Acquired Pneumonia International Cohort Study
4. **Darlene Bhavnani**, Bureau of Tuberculosis Control, Department of Health and Mental Hygiene, New York, Treatment With Three Months Of Rifapentine And Isoniazid For Tuberculosis Infection In New York City Chest Clinics
5. **Madhur Kalyan**, Post Graduate Institute of Medical Education and Research, India, Role Of HIV In Re-suscitation Of Latent Mycobacterium Tuberculosis
6. **Tyson Volkman**, CDC, Tuberculosis And Excess Alcohol Use In The United States, 1997-2012
7. **Maria Alcobia**, Centre of Pneumology, Faculty of Medicine - University of Coimbra, Portugal, Pharmacogenomics Applied To Personalized Isoniazid Treatment
8. **Lucy Burr**, Translational Research Institute, Mater Research, Australia, Peroxisome Proliferator Activated Receptor Gene Expression In The Airways Of Non Cystic Fibrosis Bronchiectasis Subjects Is Lower Than Healthy Controls And Inversely Correlated To Total Pseudomonas aeruginosa Bacterial Load At Baseline Entry Into A Clinical Trial
9. **Priya Shete**, UCSF/SFGH, Patient Costs Associated With Accessing GeneXpert® Testing In Rural Uganda
10. **Ho Namkoong**, Keio University School of Medicine, Japan, Obesity Worsens The Outcome Of Influenza Virus Infection Via Impaired IFN -Beta Induction In Mice

**Young Investigators**

1. **Eva Polverino**, Hospital Clinic IDIBAPS- CIBERES, Spain, Corticosteroids in severe community-acquired pneumonia: a multicenter, randomized, double-blind, placebo-controlled trial
2. **Daniel Salerno**, Tulane University, Utility Of Serum And Bronchoalveolar Lavage (BAL) Beta-D-Glucan Levels For The Diagnosis Of Pneumocystis Pneumonia In Patients With HIV Infection
3. **John Osterholzer**, University of Michigan Medical School and VA Ann Arbor Health System, Enhancement Of Th1 And Th17 Effector Responses By Transient Blockade Of IL-10 Signaling Promotes Fungal Clearance In Mice With Cryptococcal Lung Infection
4. **Jong Sun Park**, Seoul National University Bundang Hospital, Korea, Serum Concentrations Of Anti-Tuberculosis Drugs And Outcome Of Tuberculosis Treatment
5. **Timothy Girard**, Vanderbilt School of Medicine and VA Medical Center, Long-Term Cognitive Outcomes after Hospitalization for Community-Acquired Pneumonia (CogCAP)
6. **Walter Nicholas**, University of Colorado Denver, Anschutz Medical Campus, M tuberculosis Transcriptional Reprogramming during Human Tuberculosis
7. **Grant Theron**, University of Cape Town, South Africa, Feasibility, Accuracy And Clinical Impact Of Point-Of-Care Xpert MTB/RIF Testing For Tuberculosis In Primary-Care Settings In Africa: A Multicentre, Randomised Controlled Trial
8. **Jennifer Adjemian**, National Institute of Allergy & Infectious Disease, Laboratory of Clinical Infectious Disease, Epidemiology Unit, NIH, Nontuberculous Mycobacterial Disease Among Cystic Fibrosis Patients In The United States: Environmental Risk And NTM Screening Practices
9. **Yuichiro Shindo**, Nagoya University Graduate School of Medicine, Japan, Mortality Risks In Patients With Pneumonia Who Received Appropriate Initial Antibiotics
10. **Michael Drummond**, Johns Hopkins University, Prevalence Of Spirometric Abnormalities Among HIV-Infected Individuals
The charge of the Nominating Committee is to identify qualified MTPI members who are willing to be included as candidates for available elected leadership positions. For the upcoming elections, the Nominating Committee focused on identifying 2 candidates for the Program Chair-Elect position (1 will be elected), and 4 candidates for the Nominating Committee (2 will be elected). The Program Chair-Elect term is a 2-year position, serving as chair elect for 2014-15, and then as Program Chair for 2015-16. To reflect the primary interests of the MTPI Assembly, the nominated candidates alternate between members with primary interests in Mycobacterial infections, and members with primary interests in non-mycobacterial infections. The Nominations Committee term is a 1-year position (2014-15), and elected members work directly with the Nominating Committee Chair (appointed by the MTPI Assembly Chair). The Nominating Committee candidates reflect interests in Mycobacterial and non-mycobacterial infections as well as international membership. The Nominating Committee has identified and submitted an exceptional list of candidates, and we thank their willingness to be included on the ballot. Voting will continue in the established online format, and elected individuals will be named at the MTPI business meeting in San Diego, CA. Voting for these vital MTPI positions will begin in March – please remember to vote!

My sincere appreciation and gracious thanks to the hard-working members of the 2013-2014 MTPI Nominating Committee: Timothy Sterling, MD and Carlos Luna, MD and the invaluable administrative assistance from Syed Hassan and Miriam Rodriguez.
In early 2013, the MTPI Awards & Recognition Working Group was established with the charge to develop a new program of annual awards to recognize MTPI Assembly members for significant and meaningful contributions to the MTPI Assembly. Since the initial face-to-face meeting at the 2013 ATS Conference in Philadelphia, PA, the Working Group has been extremely active, sharing progress with the MTPI Executive Committee, to establish the framework for an inaugural program.

The MTPI Assembly is pleased to announce the creation of three new annual peer-recognition awards. The awards will recognize individuals for exemplary support and commitment to the MTPI Assembly, and for potential or recognized contributions in the areas of education and teaching, research, clinical care, mentoring or service (not limited to leadership). Annual awards will recognize individuals at different phases of career development, including Junior-level (<10 years from completing training), Mid-career level (10-20 years from completing training), and Senior level (>20 years from completing training). Candidates will be nominated by peers from the general MTPI membership, candidates voted upon by the MTPI Awards & Recognition Working Group, and a certificate presented at the 2014 MTPI Assembly Membership Meeting in San Diego, CA. Details for award qualifications and the nomination procedure are provided online (http://thoracic.org/assemblies/assembly-awards/index.php) and require a letter of nomination and the nominee’s current CV. The MTPI Senior-level awardee may be asked to speak at the 2014 MTPI Assembly Reception as a featured speaker. We look forward to this exciting new series of peer-recognition awards for deserved individuals and expect that these awards will become a highly anticipated and respected component of our annual MTPI meetings.

A tremendous thanks to the members of the MTPI Awards & Recognition Working Group, including David Lewinsohn, MD, PhD, Laurence Huang, MD, Charles Daley, MD, David Cohn, MD, Jim Beck, MD, Andy Limper, MD, and Adithya Cattamanci, MD, for comprehensive and thoughtful discussions, and the invaluable administrative assistance from Sean Slifer and Miriam Rodriguez.

This is a relatively new committee designed to help our MTPI Assembly better serve the needs of our international members. Senior and junior European, TB and non-TB experts, met last year in Philadelphia to discuss some concerns and opportunities as regards to their relationship with the annual ATS meeting. One of the main issues was the economic crisis, especially in Southern Europe, making it difficult for overseas travel and attendance at meetings such as ATS. An initiative from this committee was to propose a program of Research and Clinical Fellowships from international members to attend ATS Pulmonary Excellence Centers. This program started several years ago in the European Respiratory Society (ERS) with great success and would help to strengthen relationships between members of ATS and other international societies (such as ERS).
The MTPI assembly executive leadership started the MTPI Junior Membership Working Group several years ago. The purpose of this Working Group is to develop and implement strategies for increasing participation and membership in the MTPI assembly, with a focus on ways to facilitate leadership opportunities among our fellows and junior faculty members. Our mission and current activities include the following:

- **Develop and implement strategies for increasing membership:** Our efforts to increase membership have included the following: (1) Emailing MTPI abstract authors who are not officially members of MTPI (primary or secondary); (2) Inviting non-members to our annual orientation prior to the MTPI assembly business meeting; (3) On site sign-up sheet for active participation of junior members in the Assembly.

- **Facilitate increased participation and leadership opportunities for our fellows and junior faculty members:** This is being done through identification of interested junior members who seek to participate in MTPI committee activities, and through promotion of leadership activities at the annual ATS International Conferences as poster facilitators or chairs of ATS sessions. Our Working Group attempts to help increase the visibility and full participation of our junior and new members of MTPI by working closely with the Chair of the Assembly as well as the chairs of the various Program, Planning Committees and Working Groups. New and junior members have volunteered their time helping with Dr. Scott Evans’ effort in updating our MTPI website and in initiating new web activities such as the Webinar and Web Case Report series. We are creating an online survey to keep track of MTPI members’ interests in participation.

- **Create and update the MTPI newsletter and brochure:** We help update the annual MTPI newsletter and developed an MTPI brochure to better inform ATS members about the MTPI Assembly and encourage participation and membership.

- **Develop an MTPI Mentorship Program:** Last year, through web-based surveys and networking at the ATS meetings, we initiated a successful MTPI mentorship program. The goal was to pair interested fellows and junior faculty with more senior MTPI members in their areas of their interest. This program was very successful and this year in 2014 ATS, we will have new opportunities where we plan for the mentee-mentor pairs to meet in San Diego between the scientific sessions.

- **Work closely with ATS-wide Junior Professionals Working Group:** Our MTPI Working Group have been active participants in the ATS-wide Junior Professionals Working Group this past year, as well as the ATS MITT (Members In Transition and Training) Committee where we have representation from MTPI junior members. One of the goals was to share with and learn from other Assemblies ideas to attract new members and to develop initiatives targeting increased participation of junior members during the ATS conference. Many of these initiatives have already been in place in MTPI during the past few years. Some of the newer initiatives working with other Assemblies include plans for the following: drafting letters to program directors to market the ATS assemblies and defining their benefits, asking program directors and division chiefs to identify interested fellows and junior faculties, and sending all new members with introductory Assembly packets that can be shared with non-ATS members.

(Continued on page 8)
Our MTPI Membership Committee also includes the following: Monica Campo-Patino (Fellow, U Wash), Laura Frye (MD, UPENN), Scott Evans (Assistant Professor, MD Anderson; who is also MTPI Web/Communication Director), Sushma Cribbs (Assistant Professor, Emory), Nicholas Walter (Assistant Professor, UC Denver), and Salman Qureshi (Assistant Professor, McGill), Navneet Dhillon (PhD, KUMC), Jyotika Sharma (PhD, UND). We had our first face-to-face MTPI Membership Working Group meeting last ATS in Philadelphia. We plan to have a next MTPI Membership Working Group meeting at the ATS 2014 International Conference in San Diego, CA. Our group is particularly thankful for the work and support of Miriam Rodriguez, Sean Slifer, and Syed Hassan.

If you are interesting in any of these activities or becoming involved in our working group, we welcome your participation! Please contact us at robert.blount@ucsf.edu or charles.delacruz@yale.edu

WEB AND COMMUNICATIONS COMMITTEE REPORT
Scott Evans, MD, Web and Communications Director

Like most organizations, the MTPI Assembly is increasingly reliant on electronic media to dissemination information and to provide members a point of access. Accordingly, the Executive Committee has redoubled its efforts to provide easy access to important pulmonary infection-related content through the MTPI website.

The MTPI website features links to our many highly cited statements and positions papers, as well as links to infection-related organizations around the globe. The website also provides assembly-specific data, including leadership contacts and assembly news. In particular, look for upcoming information regarding the ATS 2014 MTPI Symposia and ongoing updates about the many important projects the MTPI Assembly supports.

In addition to the static content posted to the website, the MTPI’s efforts to provide important information related to the pathogenesis, host response, diagnosis, and management of lower respiratory tract infection now include an interactive blog and a live webinar series addressing novel, controversial, and timely issues. These series includes live presentations by international experts followed by interactive question and answer sessions from ATS members from all Assemblies. This past year, we have had two highly successful webinar sessions: (1) “The Deleterious Effects of Cigarette Smoke Exposure on Tuberculosis Infection, Disease and Prognosis” by Drs. Megan Murray and Keertan Dheda and (2) “Health Care-Associated Pneumonia (HCAP): Pathophysiology, Diagnosis and Treatment by Drs. Richard Wunderink and Scott Micek. Another important web-based activity of the Assembly is the contribution of cases to the ATS Clinical Cases section. This is an excellent opportunity to publish a peer-reviewed pulmonary infection-related case, and submissions are welcomed from both faculty and fellows. Assistance with formatting and submission will be provided by the MTPI Web Committee.

To reach the MTPI website from the ATS Home (thoracic.org), hover over the “Assemblies” tab on the upper blue ribbon, and select “Microbiology, Tuberculosis and Pulmonary Infections” to gain immediate access to all of the updated content.

For the webinar, the contact is: Ritwij Kulkarni, rkulkarni@lsu.edu; For the blog, the contacts are: Monica Campo, MCampo@medicine.washington.edu; and Claudia Dobler, c.dobler@unsw.edu.au; For the case reports, the contact is: Min Wu, min.wu@med.und.edu

MTPI members who are interested in submitting ATS Clinical Cases, providing updated links, suggesting webinar topics, participating in the MTPI Web Committee or otherwise contributing ideas to improve the website are encouraged to contact Scott Evans at seevans@mdanderson.org
INITIAL EXPLORATORY MEETING:
LUNG INFECTIONS INTEREST GROUP

The increasing variety and frequency of multi-drug resistant bacterial pathogens and other severe lung infections present great challenges to ATS clinicians and clinical researchers. An interdisciplinary interest group is needed to advance the interest of the American Thoracic Society in this important area.

An inaugural exploratory meeting is planned on Monday, May 19th, 2014 from 12 noon to 1:30 PM at the Manchester Grand Hyatt San Diego in Balboa A (2nd Floor). The Microbiology, Tuberculosis & Pulmonary Infections Assembly will be the initial sponsor but actively encourages participation from interested members of the Clinical Problems, Section on Terrorism/Inhalation Disasters, and Critical Care Assemblies.

The primary goal of this meeting is to gauge ATS member interest in this group and to discuss specific areas of need. Potential topics include but are absolutely not limited to the following:

- Recommend Working group(s) to address specific areas of concern/interest. These areas would be outside the scope of current guidelines and committees because of limited evidence base.
- Encourage collaboration with industry and government to form a collaborative clinical trials group.
- Develop/review and refine endpoints for clinical trials in acute serious lung infections.
- Propose and develop workshops with subsequent publication of discussion summary (similar to prior MTPI-sponsored workshops for Pneumocystis and HIV-lung disease)

The ultimate goal will be to help re-establish the ATS annual meeting as the premier international event for experts and policymakers to share advances in the diagnosis, treatment and control of serious lung infections.

We look forward to your participation and a robust discussion of this important area of pulmonary and critical care medicine. Rich Wunderink; r-wunderink@northwestern.edu.
Assembly on Microbiology, Tuberculosis and Pulmonary Infections
Membership Meeting

Monday, May 19th
5:00pm-7:00pm
Manchester Grand Hyatt San Diego
Harbor Ballroom B-C
Second Floor

Assembly on Microbiology, Tuberculosis and Pulmonary Infections
Reception

Monday, May 19th
7:00pm-10:00pm
Manchester Grand Hyatt San Diego
Harbor Ballroom A
Second Floor

Submit an Assembly/Committee Project Application for funding in FY2015!

We are happy to announce that ATS will once again accept NEW Assembly/Committee Projects for FY2015. All interested applicants should begin developing their ideas for Assembly/Committee Project Applications. Applications will be available on the ATS website at www.thoracic.org.

Please consider submitting an application for an Assembly/Committee project. If you have a suggestion for a project application and you need assistance, please contact your Assembly Planning Committee Chair Joseph M. Keane, MD at jkeane@stjames.ie

Please contact Miriam Rodriguez with any questions at tel: 212/315-8639 or email: mrodriguez@thoracic.org.
Help Us Help You!

Have you moved, changed your title, added new skills, credentials or other information? ATS members can now update their contact information, assembly affiliations, and demographic profile quickly and easily online with the Member Profile Update form.

Keeping your profile current ensures accuracy during the ATS International Conference registration process and also helps the ATS provide you with valuable member benefits. To streamline the process, the ATS has updated and combined demographic categories, which makes it easier for you to send us pertinent information to serve you better.

The Member Profile Update form is safe and secure, and your updates will be reflected immediately in our database. Please take a minute to login and update your member record today at [http://www.thoracic.org/login/ats-member-login.php?rl=https://thoracic.secure.force.com/MPU](http://www.thoracic.org/login/ats-member-login.php?rl=https://thoracic.secure.force.com/MPU)

At this same web link members can now also print their own, personalized membership certificate!

Please join us in honoring William W. Busse, MD, during ATS 2014 in San Diego on Saturday, May 17, at 7 p.m., at the Sixth Annual American Thoracic Society Foundation Research Program Benefit.

His impassioned advocacy and generosity towards the ATS Foundation Research Program has given promising young investigators in pulmonary, critical care, and sleep medicine a “lifeline” at a crucial moment in their careers. Because Dr. Busse’s clinical and research interests are central to both the ATS and the AAAAI, the Foundation invites friends and colleagues in both organizations to celebrate his remarkable dedication to helping patients.

There are several ways you may pay tribute to Dr. Busse:

- If you are planning to attend ATS 2014, please register for the Benefit at [http://www.thoracic.org/go/benefit](http://www.thoracic.org/go/benefit).
- If you are unable to attend the Benefit but wish to place an ad or make a donation to the Research Program in honor of Dr. Busse, please visit [http://www.thoracic.org/go/benefitcontributions](http://www.thoracic.org/go/benefitcontributions).

For more information, contact ErinMarie Nebel at EMNebel@thoracic.org or at 212-315-6464.

Every dollar contributed will go directly to support research awards for early career scientists.
Since first published in 2006, the International Standards for Tuberculosis Care (ISTC) has promoted and facilitated high quality tuberculosis services for patients with or suspected of having the disease in both the public and private health care sectors globally. Because of the process by which the ISTC was developed and the international endorsements it has received through the two previous editions, the document is authoritative and broadly credible. The ISTC has been translated into more than 15 languages, endorsed by more than 50 international and national organizations, and is widely used by tuberculosis control programs globally.

Much of the information presented in the ISTC is derived from existing WHO documents. Thus, the ISTC serves as a compendium of recommendations and guidelines developed by a rigorous, evidence-based process and presents the information in a context more suited to clinical care while at the same time emphasizing the public health responsibilities inherent in providing tuberculosis services. Taken together these documents provide comprehensive guidance for best practices in tuberculosis care and control.

Edition 1 of the ISTC stated, “The Standards should be viewed as a living document that will be revised as technology, resources, and circumstances change.” It has now been five years since Edition 2 of the ISTC was published (2009); new information has emerged; new approaches are now feasible; and new guidelines have been written. These changes warrant an updating of the ISTC to be consistent with the concept of a “living document.”

After decades of dormancy, the technology available for tuberculosis care and control is now rapidly evolving. In particular, rapid molecular testing using devices with excellent performance characteristics for detecting Mycobacterium tuberculosis and rifampin resistance, and are practical and affordable for use in decentralized facilities in low resource settings are being widely deployed globally. Used appropriately, both within tuberculosis control programs and in private laboratories, these devices have the potential to revolutionize tuberculosis care and control, providing a confirmed diagnosis and a determination of rifampin resistance within a few hours enabling appropriate treatment to be initiated promptly. Thus, the most numerous and dramatic changes in global recommendations since the 2009 edition are related to the routine use of rapid molecular tests. Additional important changes include: emphasis on the recognition of groups at increased risk of tuberculosis; updating the standard on antiretroviral treatment in persons with tuberculosis and HIV infection; and revising the standard on treating multiple drug resistant tuberculosis.

Although the principles of care that underlie the ISTC will not change, the ways in which they are applied will evolve. A challenging aspect of the hoped for evolution will be (already is) providing rapid updates of guidance documents such as the ISTC. To approach this challenge we intend to make the ISTC primarily an electronic document with applications through which updates can rapidly and automatically be delivered. Through this and other yet to be defined mechanisms we hope to achieve the full engagement of all sectors of the healthcare system in delivering high quality tuberculosis diagnostic, treatment and preventive services.

www.thoracic.org/assemblies/mtpi/resources/iste-report.pdf

www.thoracic.org/assemblies/mtpi/resources/ISTC-mobile-app.docx

ISTC documents and related training and education materials
www.istcweb.org
In 2014, the ATS Public Advisory Roundtable (PAR) continues its successful program "Lung Disease Week at the ATS," which represents a society-wide initiative to recognize the many rare lung disorders for which ATS PAR member organizations provide support and guidance to patients and their families. For a series of one-week periods throughout 2014 ATS PAR will bring patient issues to the front and center of the Society's agenda. Working with its PAR partners, the ATS will develop, aggregate and host links to disease-specific content on its Web site. Material will include patient stories, testimonials, interviews, videos, photos, support group information, details on ongoing legislative efforts and clinical trial updates. The ATS will foster interaction between patients, clinicians and researchers by hosting online question-and-answer sessions, Webinars and/or podcasts featuring lung disease experts. See the full calendar of lung disease weeks below.

<table>
<thead>
<tr>
<th>2014 Date</th>
<th>Disease Week</th>
<th>PAR Member</th>
<th>ATS Board Member</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb 9-15</td>
<td>Sarcoidosis</td>
<td>Andrea Wilson (Foundation for Sarcoidosis Research)</td>
<td>Carrie Redlich, MD</td>
</tr>
<tr>
<td>Mar 2-8</td>
<td>Cystic Fibrosis</td>
<td>Beth Sufian (Cystic Fibrosis Foundation)</td>
<td>Samya Nasr, MD</td>
</tr>
<tr>
<td>Apr 6-12</td>
<td>ARDS</td>
<td>Eileen Rubin (ARDS Foundation)</td>
<td>Shannon Carson, MD</td>
</tr>
<tr>
<td>Apr 20-26</td>
<td>Sleep Disorders</td>
<td>Ed Grandi (American Sleep Apnea Association)</td>
<td>Atul Malhotra, MD</td>
</tr>
<tr>
<td>Jun 1-7</td>
<td>LAM</td>
<td>Mary Harbaugh (The LAM Foundation)</td>
<td>Charlie Strange, MD</td>
</tr>
<tr>
<td>Jun 22-28</td>
<td>Scleroderma</td>
<td>Kerri Connolly (Scleroderma Foundation)</td>
<td>Nick Hill, MD (ATS Past President)</td>
</tr>
<tr>
<td>July 6-12</td>
<td>Pulmonary Hypertension</td>
<td>Debbie Castro (Pulmonary Hypertension Association)</td>
<td>Jason Yuan, MD</td>
</tr>
<tr>
<td>Aug 3-9</td>
<td>chILD</td>
<td>Greg Porta (chILD Foundation)</td>
<td>Robin Deterding, MD</td>
</tr>
<tr>
<td>Aug 24-30</td>
<td>Rare Lung Diseases</td>
<td>Jack Kelly (Lymphangiomatosis &amp; Gorham’s Disease Alliance)</td>
<td>Jess Mandel, MD</td>
</tr>
</tbody>
</table>

*Also local onsite event*
<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Speaker</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sep 7-13</td>
<td>Lung Transplant</td>
<td>Jeff Goldstein</td>
<td>(Lung Transplant Foundation)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Also local onsite event</em></td>
<td></td>
</tr>
<tr>
<td>Sep 21-27</td>
<td>Pulmonary Fibrosis</td>
<td>Teresa Barnes</td>
<td>(Coalition for Pulmonary Fibrosis)</td>
</tr>
<tr>
<td>Oct 5-11</td>
<td>Asthma</td>
<td>Charlotte Collins</td>
<td>(Asthma &amp; Allergy Foundation of America)</td>
</tr>
<tr>
<td>Nov</td>
<td>Lung Cancer</td>
<td>Regina Vidaver</td>
<td>(Free to Breathe, formerly NLCP)</td>
</tr>
<tr>
<td>Dec 7-13</td>
<td></td>
<td>Linda Nici, MD</td>
<td></td>
</tr>
</tbody>
</table>